Skip to main content
Top
Published in: Journal of Neural Transmission 3/2017

01-03-2017 | Neurology and Preclinical Neurological Studies - Original Article

Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson’s disease

Authors: Jian Ding, Jiejin Zhang, Xixi Wang, Li Zhang, Siming Jiang, Yongsheng Yuan, Junyi Li, Lin Zhu, Kezhong Zhang

Published in: Journal of Neural Transmission | Issue 3/2017

Login to get access

Abstract

The aim of our study is to examine the plasma levels of the four kinds of neurodegenerative proteins in plasma: α-syn, T-tau, P-tau181, and Aβ-42 in Parkinson’s disease (PD) and to evaluate the relationship between their plasma levels and PD motor subtypes. 84 patients with PD were enrolled in our study, and finally, 73 of them were classified into the tremor-dominant subtype (TD) and the postural instability gait difficulty subtype (PIGD). Their motor performance was evaluated by a series of clinical assessments: Freezing of Gait Questionnaire (FOGQ), Timed Up and Go (TUGs), Tinetti balance, and Tinetti gait. Plasma levels of these proteins were measured by enzyme-linked immunosorbent assay (ELISA). The plasma level of α-syn was significantly higher in PD patients when compared to controls (p = 0.004), and significantly higher in the PIGD group when compared to the TD group (p = 0.03). While the plasma level of Aβ-42 was significantly lower in PD patients than in controls (p = 0.002), and significantly lower in the PIGD group than in the TD group (p = 0.05). In PD patients, the plasma level of α-syn (r = −0.355, p < 0.001) was significantly related to the severity of Tenitti Gait score, even after performing multiple linear regression (p = 0.002). While the plasma level of Aβ-42 (r = −0.261, p < 0.05) was significantly associated with the severity of PIGD score and remained correlate when performed multiple linear regression (p = 0.005). The patients with PIGD subtype are characterized with a lower level of plasma Aβ-42 and a higher plasma level of α-syn, which may be used as biomarkers for diagnosis and progression of the subtypes of PD.
Literature
go back to reference Alves G, Pedersen KF, Bloem BR et al (2013) Cerebrospinal fluid amyloid-beta and phenotypic heterogeneity in de novo Parkinson’s disease. J Neurol Neurosurg Psychiatry 84(5):537–543CrossRefPubMed Alves G, Pedersen KF, Bloem BR et al (2013) Cerebrospinal fluid amyloid-beta and phenotypic heterogeneity in de novo Parkinson’s disease. J Neurol Neurosurg Psychiatry 84(5):537–543CrossRefPubMed
go back to reference Atik A, Stewart T, Zhang J (2016) Alpha-Synuclein as a Biomarker for Parkinson’s Disease. Brain Pathol 26(3):410–418CrossRefPubMed Atik A, Stewart T, Zhang J (2016) Alpha-Synuclein as a Biomarker for Parkinson’s Disease. Brain Pathol 26(3):410–418CrossRefPubMed
go back to reference Auyeung M, Tsoi TH, Mok V et al (2012) Ten year survival and outcomes in a prospective cohort of new onset Chinese Parkinson’s disease patients. J Neurol Neurosurg Psychiatry 83(6):607–611CrossRefPubMed Auyeung M, Tsoi TH, Mok V et al (2012) Ten year survival and outcomes in a prospective cohort of new onset Chinese Parkinson’s disease patients. J Neurol Neurosurg Psychiatry 83(6):607–611CrossRefPubMed
go back to reference Besong-Agbo D, Elias W, Frank J et al (2013) Naturally occurring a-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology 80:169–175CrossRefPubMed Besong-Agbo D, Elias W, Frank J et al (2013) Naturally occurring a-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology 80:169–175CrossRefPubMed
go back to reference Bohnen NI, Cham R (2006) Postural control, gait, and dopamine functions in parkinsonian movement disorders. Clin Geriatr Med 22(4):797–812 (vi) CrossRefPubMed Bohnen NI, Cham R (2006) Postural control, gait, and dopamine functions in parkinsonian movement disorders. Clin Geriatr Med 22(4):797–812 (vi) CrossRefPubMed
go back to reference Duran R, Francisco JB, Blas M et al (2010) Plasma a-synuclein in patients with Parkinson’s disease with and without treatment. Mov Disord 25:489–493CrossRefPubMed Duran R, Francisco JB, Blas M et al (2010) Plasma a-synuclein in patients with Parkinson’s disease with and without treatment. Mov Disord 25:489–493CrossRefPubMed
go back to reference Fahn S, Elton RL, Committee UD (1987) Unified Parkinson’s disease rating scale. Recent Dev Parkinson's Dis 2:153–163 Fahn S, Elton RL, Committee UD (1987) Unified Parkinson’s disease rating scale. Recent Dev Parkinson's Dis 2:153–163
go back to reference Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198CrossRefPubMed Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198CrossRefPubMed
go back to reference Foulds PG, Mitchell D, Parker A et al (2011) Phosphorylated -synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson’s disease. FASEB J 25:4127–4137CrossRefPubMed Foulds PG, Mitchell D, Parker A et al (2011) Phosphorylated -synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson’s disease. FASEB J 25:4127–4137CrossRefPubMed
go back to reference Gruden MA, Davidova TV, Yanamandra K et al (2013) Nasal inoculation with alpha-synuclein aggregates evokes rigidity, locomotor deficits and immunity to such misfolded species as well as dopamine. Behav Brain Res 243:205–212CrossRefPubMed Gruden MA, Davidova TV, Yanamandra K et al (2013) Nasal inoculation with alpha-synuclein aggregates evokes rigidity, locomotor deficits and immunity to such misfolded species as well as dopamine. Behav Brain Res 243:205–212CrossRefPubMed
go back to reference Hanakawa T, Katsumi Y, Fukuyama H et al (1999) Mechanisms underlying gait disturbance in Parkinson’s disease: a single photon emission computed tomography study. Brain 122(Pt 7):1271–1282CrossRefPubMed Hanakawa T, Katsumi Y, Fukuyama H et al (1999) Mechanisms underlying gait disturbance in Parkinson’s disease: a single photon emission computed tomography study. Brain 122(Pt 7):1271–1282CrossRefPubMed
go back to reference Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184CrossRefPubMedPubMedCentral Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184CrossRefPubMedPubMedCentral
go back to reference Iacono RP, Kuniyoshi SM, Ahlman JR, Zimmerman GJ, Maeda G, Pearlstein RD et al (1997) Concentrations of indoleamine metabolic intermediates in the ventricular cerebrospinal fluid of advanced Parkinson’s patients with severe postural instability and gait disorders. J Neural Transm (Vienna) 104(4–5):451–459CrossRef Iacono RP, Kuniyoshi SM, Ahlman JR, Zimmerman GJ, Maeda G, Pearlstein RD et al (1997) Concentrations of indoleamine metabolic intermediates in the ventricular cerebrospinal fluid of advanced Parkinson’s patients with severe postural instability and gait disorders. J Neural Transm (Vienna) 104(4–5):451–459CrossRef
go back to reference Jankovic J, McDermott M, Carter J et al (1990) Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40(10):1529–1534CrossRefPubMed Jankovic J, McDermott M, Carter J et al (1990) Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40(10):1529–1534CrossRefPubMed
go back to reference Jellinger KA (2012) CSF biomarkers in different phenotypes of Parkinson disease. J Neural Transm (Vienna) 119(4):455–456CrossRef Jellinger KA (2012) CSF biomarkers in different phenotypes of Parkinson disease. J Neural Transm (Vienna) 119(4):455–456CrossRef
go back to reference Kang JH, Irwin DJ, Chen-Plotkin AS et al (2013) Association of cerebrospinal fluid beta-amyloid 1–42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 70(10):1277–1287PubMedPubMedCentral Kang JH, Irwin DJ, Chen-Plotkin AS et al (2013) Association of cerebrospinal fluid beta-amyloid 1–42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 70(10):1277–1287PubMedPubMedCentral
go back to reference Karin DD, Wesley J, Johennes AH et al (2013) Cerebrospinal fliud and plasma clusterin levels in Parkinson’s disease. Parkinsonism Relat Disord 19(12):1079–1083CrossRef Karin DD, Wesley J, Johennes AH et al (2013) Cerebrospinal fliud and plasma clusterin levels in Parkinson’s disease. Parkinsonism Relat Disord 19(12):1079–1083CrossRef
go back to reference Kegelmeyer DA, Kloos AD, Thomas KM et al (2007) Reliability and validity of the Tinetti Mobility Test for individuals with Parkinson disease. Phys Ther 87(10):1369–1378CrossRefPubMed Kegelmeyer DA, Kloos AD, Thomas KM et al (2007) Reliability and validity of the Tinetti Mobility Test for individuals with Parkinson disease. Phys Ther 87(10):1369–1378CrossRefPubMed
go back to reference Lee PH, Lee G, Park HJ et al (2006) The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophy. J Neural Transm (Vienna) 113(10):1435–1439CrossRef Lee PH, Lee G, Park HJ et al (2006) The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophy. J Neural Transm (Vienna) 113(10):1435–1439CrossRef
go back to reference Lehallier B, Essioux L, Gayan J et al (2015) Combined plasma and cerebrospinal fluid signature for the prediction of midterm progression from mild cognitive impairment to Alzheimer disease. JAMA Neurol 2015:1–10 Lehallier B, Essioux L, Gayan J et al (2015) Combined plasma and cerebrospinal fluid signature for the prediction of midterm progression from mild cognitive impairment to Alzheimer disease. JAMA Neurol 2015:1–10
go back to reference Li QX, Mok SS, Laughton KM et al (2007) Plasma α-synuclein is decreased in subjects with Parkinson’s disease. Exp Neurol 204:583–588CrossRefPubMed Li QX, Mok SS, Laughton KM et al (2007) Plasma α-synuclein is decreased in subjects with Parkinson’s disease. Exp Neurol 204:583–588CrossRefPubMed
go back to reference Majbour NK, Vaikath NN, Eusebi P et al (2016) Longitudinal changes in CSF alpha-synuclein species reflect Parkinson’s disease progression. Mov Disord 31(10):1535–1542CrossRefPubMed Majbour NK, Vaikath NN, Eusebi P et al (2016) Longitudinal changes in CSF alpha-synuclein species reflect Parkinson’s disease progression. Mov Disord 31(10):1535–1542CrossRefPubMed
go back to reference Menzie J, Pan C, Prentice H et al (2014) Taurine and central nervous system disorders. Amino Acids 46(1):31–46CrossRefPubMed Menzie J, Pan C, Prentice H et al (2014) Taurine and central nervous system disorders. Amino Acids 46(1):31–46CrossRefPubMed
go back to reference Molina JA, Jiménez-Jiménez FJ, Gomez P et al (1997) Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson's disease. J Neurol Sci 150(2):123–127CrossRefPubMed Molina JA, Jiménez-Jiménez FJ, Gomez P et al (1997) Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson's disease. J Neurol Sci 150(2):123–127CrossRefPubMed
go back to reference Ohrfelt A, Grognet P, Andreasen N et al (2009) Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett 450(3):332–335CrossRefPubMed Ohrfelt A, Grognet P, Andreasen N et al (2009) Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett 450(3):332–335CrossRefPubMed
go back to reference Park MJ, Cheon SM, Bae HR et al (2011) Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson’s disease. J Clin Neurol 7:215–222CrossRefPubMedPubMedCentral Park MJ, Cheon SM, Bae HR et al (2011) Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson’s disease. J Clin Neurol 7:215–222CrossRefPubMedPubMedCentral
go back to reference Parkkinen L, Soininen H, Laakso M et al (2001) Alpha-synuclein pathology is highly dependent on the case selection. Neuropathol Appl Neurobiol 27(4):314–325CrossRefPubMed Parkkinen L, Soininen H, Laakso M et al (2001) Alpha-synuclein pathology is highly dependent on the case selection. Neuropathol Appl Neurobiol 27(4):314–325CrossRefPubMed
go back to reference Ritz B, Rhodes SL, Bordelon Y et al (2012) a-synuclein genetic variants predict faster motor. Symptom progression in idiopathic Parkinson disease. PLoS One 7:e36199CrossRefPubMedPubMedCentral Ritz B, Rhodes SL, Bordelon Y et al (2012) a-synuclein genetic variants predict faster motor. Symptom progression in idiopathic Parkinson disease. PLoS One 7:e36199CrossRefPubMedPubMedCentral
go back to reference Shumway-Cook A, Brauer S, Woollacott M (2000) Predicting the probability for falls in community-dwelling older adults using the Timed Up & Go Test. Phys Ther 80(9):896–903PubMed Shumway-Cook A, Brauer S, Woollacott M (2000) Predicting the probability for falls in community-dwelling older adults using the Timed Up & Go Test. Phys Ther 80(9):896–903PubMed
go back to reference Tomlinson CL, Stowe R, Patel S et al (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25(15):2649–2653CrossRefPubMed Tomlinson CL, Stowe R, Patel S et al (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25(15):2649–2653CrossRefPubMed
go back to reference Wang XY, Kang WY, Yang Q et al (2014) Using gastrocnemius sEMG and plasma alpha-synuclein for the prediction of freezing of gait in Parkinson’s disease patients. PLoS One 9(2):e89353CrossRefPubMedPubMedCentral Wang XY, Kang WY, Yang Q et al (2014) Using gastrocnemius sEMG and plasma alpha-synuclein for the prediction of freezing of gait in Parkinson’s disease patients. PLoS One 9(2):e89353CrossRefPubMedPubMedCentral
go back to reference Yu X, He GR, Sun L et al (2012) Assessment of the treatment effect of baicalein on a model of Parkinsonian tremor and elucidation of the mechanism. Life Sci 91(1–2):5–13CrossRefPubMed Yu X, He GR, Sun L et al (2012) Assessment of the treatment effect of baicalein on a model of Parkinsonian tremor and elucidation of the mechanism. Life Sci 91(1–2):5–13CrossRefPubMed
Metadata
Title
Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson’s disease
Authors
Jian Ding
Jiejin Zhang
Xixi Wang
Li Zhang
Siming Jiang
Yongsheng Yuan
Junyi Li
Lin Zhu
Kezhong Zhang
Publication date
01-03-2017
Publisher
Springer Vienna
Published in
Journal of Neural Transmission / Issue 3/2017
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-016-1650-2

Other articles of this Issue 3/2017

Journal of Neural Transmission 3/2017 Go to the issue

High Impact Review in Neuroscience, Neurology or Psychiatry - Review Article

Speech disorders in Parkinson’s disease: early diagnostics and effects of medication and brain stimulation

Neurology and Preclinical Neurological Studies - Original Article

Motion and emotion: anxiety–axial connections in Parkinson’s disease

Neurology and Preclinical Neurological Studies - Original Article

Attention in Parkinson’s disease with fatigue: evidence from the attention network test

Neurology and Preclinical Neurological Studies - Original Article

Brain structural profile of multiple system atrophy patients with cognitive impairment

Neurology and Preclinical Neurological Studies - Original Article

A prospective evaluation of taste in Parkinson’s disease